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Abstract The lipid responsiveness of the structurally unique protein kinase, referred to as PAK-1, recently isolated from rat liver [(1994) J. Biol. 
Chem. 269, in press], is characterised bythe high sensitivity (low micromolar) of its ribosomal $6(229-239) peptide kinase activity to both cardiolipin 
and the cis-unsaturated fatty acids and insensitivity to phosphatidylserine. Autophosphorylation f PAK-1 exhibited even greater sensitivity 
(submicromolar) to cardiolipin, but was relatively less affected by phosphatidylserine. Oleate, the most potent activator of PAK-l's peptide kinase 
activity was relatively ineffectual with autophosphorylation. These and other unusual characteristics, including high levels of basal catalytic activities, 
suggest a novel mechanism of regulation distinct from that of the protein kinase Cs 
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1. Introduction 
Recently, we reported the purification and characterisation 
of a structurally novel cardiolipin and protease-activated 116 
kDa protein kinase from rat liver (referred to as PAK-1; [1]). 
Liver PAK- 1 resembles the protein kinase C (PKC) isoenzymes 
with regard to its ability to efficiently phosphorylate ribosomal 
$6 peptide analogues [2], as well as its cardiolipin and protease 
activatability [1]. However, the enzyme displays different sub- 
strate preferences, is unresponsive to Ca 2+ and phosphatidyls- 
erine/phorbol ester and is insensitive to the PKC-~(19-31) 
pseudosubstrate inhibitor peptide [1]. The complete amino acid 
sequence of liver PAK-1 [26] closely resembles that of the re- 
cently cloned human hippocampus and rat lung PKN sequence 
(99.5% identity) [3]. While the regulatory domain sequence is 
unrelated to that of any previously defined protein kinase, the 
amino acid sequence of its catalytic domain most closely resem- 
bles the corresponding sequences of the PKC isozymes (ca. 50% 
sequence identity). This similarity, together with the phospho- 
lipid sensitivity of PAK-1, suggests that the PKCs might serve 
as useful models for investigating the mechanism of regulation 
of liver PAK-1. 
The PKCs are structurally and functionally a diverse family 
of enzymes which includes the calcium-dependent (~,ill, fllI 
and Z) and independent (8, e, r /and 0) and the atypical (~', 2 
and ft) isoenzymes [4-10]. All of the known PKCs are activated 
by phosphatidylserine, but not all are responsive to diacylglyc- 
erol or phorbol ester [5-8]. Other acidic phospholipids and 
various cis-unsaturated fatty acids can activate PKC isoen- 
zymes with or without diacylglycerol (or phorbol esters) [5,9- 
l 1]. The calcium-independent a d atypical isoenzymes, most 
resemble PAK-1 in that they exhibit less stringent dependency 
for phosphatidylserine and are more responsive to non- 
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Abbreviations." PAK-I, protease activated protein kinase 1; PKC, pro- 
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nositol; CL, cardiolipin; PA, phosphatidic a id; TPA, 12-tetradecanoyl 
phorbol 13-acetate. 
phosphatidylserine lipids than the calcium-dependent PKC 
isoenzymes [5,10]. 
Here we further define the responsiveness of liver PAK-1 to 
various acidic phospholipids and cis-unsaturated fatty acids 
both with respect o its peptide kinase and autophosphoryla- 
tion activities. 
2. Materials and methods 
2.1. Materials 
Phospholipids (PA, PG and C1 as sodium salts; PI as ammonium salt; 
PC, PS and PE as free lipids), fatty acids (free acid) and diacylglycerol 
were purchased from Sigma. [z-nP]ATP was from Bresatec Australia. 
Rat liver PAK-I was purified to homogeneity asdescribed previously 
[1] and assayed with the synthetic peptide, Alang-Lys-Arg-Arg-Arg- 
Leu-Ser-Ser-Leu-Arg-Ala-(NH2) 239, based on ribosomal protein $6 res- 
idues 229-239 [2]. The $6(229-239) peptide was synthesised on an 
Applied Biosystems 430A peptide synthesiser, using a simplified auto- 
mated t-Boc solid phase peptide synthesis and reversed phase HPLC 
purification protocols based on the method of Schn61zer tal. 1992 [12], 
as modified by Mansell and Fecondo (in preparation). Brain PKC was 
prepared as described previously [13]. 
2.2. Experimental procedures 
Lipids were prepared in chloroform, dried under a stream of nitro- 
gen, and sonicated into 20 mM Tris-HCl, pH 7.5, at 20/tm for 4 × 15 s 
using an MSE sonicator. Dilutions were made in the same buffer with 
vigourous vortexing. Lipid-dependent PAK-1 activity was determined 
in a reaction mixture containing 20 mM Tris-HCl, pH 7.6, 5 mM 
MgCI2, 40 mM KCI, 0.2 mM ATP (10-100 cpm/pmol), 30/IM $6(229- 
239), 1 mM EGTA, 1 mM EDTA, 1 mM dithiothreitol, 2.5% (v:v) 
ethandiol, 0.0025% (v:v) Brij-35 (originating from storage buffer for 
purified PAK, [1]) and 0.1 mg/ml soyabean trypsin inhibitor, incubated 
with or without lipid additions for 10 min at 30°C as described previ- 
ously [1]. 
2.3. Autophosphorylation of PAK-1 
PAK-1 was incubated with 20 mM Tris-HC1, pH 7.5, 5 mM MgC12, 
40 mM KC12, 1 mM EGTA, 1 mM EDTA, 1 mM dithiothreitol, 50/IM 
[Z-32p]ATP (1,000-3,000 cpm/pmol), 0.0025% Brij-35 and 2.5% ethan- 
diol, at 30°C for the indicated times in the presence and absence of 
lipids at the concentration specified in the figure legends. The fatty acid 
and phospholipid preparations were identified to those used in the 
$6(229-239) peptide kinase assays. The reaction was terminated by the 
addition of Laemelli SDS sample buffer [14] and the 32p-labelled protein 
resolved by 7.5% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
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and subsequently detected by autoradiography using Kodak X-AR film 
and quantitated by densitometry (Molecular Dynamics Densitometer). 
3. Resu l ts  
3.1. Lipid activators of PAK-1 ribosomal $6 peptide kinase 
activity 
Potential lipid regulators of purified liver PAK-1 were as- 
sessed using the ribosomal protein $6(229-239) peptide sub- 
strate, previously characterised asa low Km (ca. 3.4 HM) sub- 
strate for the enzyme [1,2]. Initial screening with phospholipids 
and fatty acids at concentrations of 10 Hg/ml and 20/.tM, 
respectively, confirmed Ca2+-independent activation of PAK-1 
by acidic phospholipids other than phosphatidylserine, and 
showed the cis-unsaturated fatty acids also to be potent activa- 
tors (Table 1). Several of the lipids, particularly oleic acid, 
arachidonic acid and cardiolipin, were even more effective than 
trypsin in the activation of the enzyme (Table 1). The saturated 
stearic and palmitic acids also stimulated activity, but to a lesser 
extent han the C18 to C20 unsaturated fatty acids (Table 1, 
Fig. 1). Fatty acid dosage dependency studies howed activa- 
Table 1 
Effects of modifiers on PAK-I activity 
Modifier Relative peptide kinase activity (%) 
PAK-1 Brain PKC 
None 100 
10/lg/ml Cardiolipin 377 
10 ~tg/ml Phosphatidylglycerol 344 
10 Jtg/ml Phosphatidylcholine 100 
10/tg/ml Phosphatidylethanol- 
amine 100 
10/~g/ml Phosphatidylinositol 282 
10/lg/ml Phosphatidic acid 226 
20 tiM Stearic acid 240 
20/~M Palmitic acid 175 
20/IM Oleic acid 577 
20/.tM Arachidonic acid 348 
Trypsin (standard PAK 
activation conditions) 330 
1 mM EGTA 100 100 
0.5 mM Ca 2+ 86 219 
100/.tg/ml PS/I mM EGTA 103 273 
100 ~tg/ml PS/0.5 mM Ca 2+ 90 2276 
100 Hg/ml PSI50 nM TPA/ 
1 mM EGTA 99 1338 
100 Hg/ml PSI50 nM TPA/ 
0.5 mM Ca 2÷ 90 2573 
50 nM TPA/1 mM EGTA 86 151 
50 nM TPA/0.5 mM Ca 2+ 85 493 
Purified PAK-1 was assayed for $6(229-239) peptide kinase activity 
without rypsin activation, with or without various phospholipids, fatty 
acids, TPA or CaC12 (Ca2+). Peptide kinase activity (relative activity) 
was expressed asa percentage of that obtained for PAK-1 or brain PKC 
with no additions (6.1 and 3.3 pmol/min, respectively). The activity 
obtained with trypsin activation of this PAK-I preparation (see refer- 
ence for standard activation procedure) was 16.4 pmol/min and the 
activity obtained with phospholipid/TPA/Ca 2+ ctivation of the brain 
PKC preparation was 84.9 pmol/min. These results are representative 
of a number of similar experiments with different preparations of 
PAK-1. 
500 
~ 100 
I 
1 10 100 
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Fig. 1. Fatty acid dependency of PAK-1 peptide kinase activity: PAK-1 
was assayed with 30/.tM $6(229-239) asdescribed in section 2 with 
sonicated dispersions ofthe following lipids; oleic acid (D), arachidonic 
acid (©), linoleic acid (@), linolenic acid (m) and stearic acid (A). Peptide 
kinase activity is expressed as a percentage of that obtained in the 
absence of lipids (100%). 
tion followed by inhibition of the PAK-1 peptide kinase activity 
(Fig. 1), a pattern resembling that observed previously with 
cardiolipin [1]. 
The stimulatory effects of the acidic phospholipids and cis- 
unsaturated fatty acids were only observed with sonicated prep- 
arations of lipids (Table 1) and were suppressed by the addition 
of the non-ionic detergent Triton X-100 at the low concentra- 
tion (0.01%) sufficient to form the mixed micelles that support 
phosphatidylserine activation of the PKCs [15] (not illustrated). 
To eliminate the possibility that any effect of phosphatidyl- 
serine on PAK-1 was specifically interferred with by the deter- 
gent Brij-35 (0.0025%) present in the standard PAK assay reac- 
tion mixture (see section 2), the screening lipids was carried out 
in the absence of detergent (cf. [1]). Under these conditions, the 
phosphatidylserine pr paration had no effect on PAK-1 pep- 
tide kinase activity, but was fully effective in the activation of 
brain PKC (20-30-fold stimulation) (Table 1). The relatively 
greater maximal stimulation of brain PKC by phospholipid 
(20-30-fold), compared with the 3~,-fold lipid stimulation of 
PAK-1 activity under the same conditions, is a characteristic 
difference between the two enzymes (Table 1). This primarily 
reflected the relatively low level of basal activity of PKC prep- 
arations, with the specific activities of the fully lipid-activated 
PAK- 1 and PKCs being of the same order of magnitude (Table 
2) [1]. Unlike the PKCs, the activation of PAK-I by either the 
phospholipids or fatty acids did not display synergy or additive 
effects with either diacylglycerol r TPA (not illustrated) [1], 
and the addition of either of these activators had no effect in 
the presence of phosphatidylserine (Table 1). 
The Vma x values for $6 peptide phosphorylation showed that 
the C18 and C20 cis-unsaturated fatty acids were the most 
potent overall activators of PAK-1 (Table 2). The lower Vm,x 
values for the saturated stearic and palmitic acids, and the 
various acidic phospholipid activators, i.e. < 65% of the values 
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for oleic acid (Table 2), suggested that the inhibitory effects of 
higher concentrations oflipids (e.g. Fig. 1) [1] became dominant 
before full activation of the enzyme was achieved. While overall 
oleic acid was the most effective of all of the activators tested, 
the ECs0s for cardiolipin and phosphatidylinositol (1.7 and 
3.1/aM, respectively) were lower than for oleic acid (4.2/aM) 
(Table 2). This indicated that these phospholipids interated 
with PAK-1 at least as efficiently as oleic acid. Their inability 
to elicit full activation may have reflected the formation of 
inhibitory higher order lipid structures below the lipid concen- 
tration required for full activation. 
A comparison of the ECso values for the series of C18 fatty 
acids established that a critical structural feature determining 
the sensitivity of PAK-1 was the C9-10 double bond, the intro- 
duction of which (i.e. oleic versus stearic acids) caused a 
> 3-fold reduction in the ECs0 and increased the maximal acti- 
vation nearly 2-fold (Table 2). Additional double bonds had a 
negative influence with the ECs0s increasing from 4.2/aM for 
oleic, to 8.0/aM for linoleic, to 19.7/aM for linolenic (Table 2). 
The relatively high ECs0s of 72.1 /aM for palmitic acid com- 
pared with 14.3/aM for stearic acid, (Table 2), indicated that 
carbon chain length is also an important determinant of the 
efficacy of fatty acids as PAK-1 activators. 
3.2. Differential effects of  lipids on PAK-1 autophosphorylation 
To further assess the lipid responsiveness of PAK-1, the 
effects of the various lipid activators of peptide kinase activity 
on the autophosphorylation activity of the enzyme were inves- 
tigated, thus eliminating potential complications due to lipid- 
peptide substrate interactions as can occur with PKCs [16]. 
Incubation of purified PAK-1 with [y-32p]ATP resulted in the 
rapid autophosphorylation of the 116 kDa PAK-1 polypeptide 
(Fig. 2). In the absence of any activators, autophosphorylation 
approached a maximum stoichiometry of about 1 mol phos- 
phate per mol enzyme within 30 min of incubation (Fig. 3; time 
course not illustrated). Both the rate (not illustrated) and stoi- 
chiometry (Figs. 2 and 3) of PAK-1 autophosphorylation were 
stimulated by cardiolipin. While the magnitude of the cardiol- 
Table 2 
Lipid dependence of PAK-I 
Lipid ECs0 Vmax 
(,umol/min/mg) 
Cardiolipin 1.7 
Phosphatidylinositol 3.1 
Phosphatidylglycerol 7.8 
Phosphatidic acid 15.9 
Oleic acid 4.2 
Arachidonic acid 10.1 
Linoleic acid 8.0 
Linolenic acid 19.7 
Palmitic acid 72.1 
Stearic acid 14.3 
uM 3.67 
uM 3.03 
uM 3.40 
uM 3.28 
uM 5.62 
uM 4.34 
uM 4.28 
uM 5.09 
uM 3.40 
uM 3.09 
PAK-1 was assayed with the following lipids using 30 pM $6(229-239) 
as substrate. The concentration yielding half maximal activity of PAK- 
1 is expressed as an ECs0 value. Phospholipid concentrations were 
calculated assuming that the M r values for the following analogues 
approximated to the average M r values of the corresponding atural 
phospholipid preparations. Cardiolipin (tetra linoleyl; di-sodium salt, 
M r = 1491.9), phosphatidylinositol (1-stearic, 2-arachidonyl; ammo- 
nium salt, M r --- 906.2), phosphatidylglycerol (l,2-dioleoyl; sodium salt, 
Mr=797) and phosphatidic acid (1,2-dimyristyl; sodium salt, 
Mr = 614.8). 
I<Da 
205 
116 
94 
68 - -  
45 - -  
30 - -  
- OL CL P l PG PC PE PS 
Fig, 2. Lipid dependency ofPAK-1 autophosphorylation: PAK-I (0.1 
/tg) was incubated in the presence of 50/.tM ATP for 20 min with either 
10/tM fatty acid or 20/.tg/ml phospholipid; no addition (-), oleic acid 
(OL), cardiolipin (CL), phosphatidylinositol (PI),phosphatidylglycerol 
(PG), phosphatidylcholine (PC), phosphatidylethanolamine (PE) and 
phosphatidylserine (PS). 32P-Labelled PAK-I was resolved by 7.5% 
SDS-PAGE and detected by autoradiography. The relative percentage 
of PAK-I autophosphorylation determined from densitometry were; 
control, 100%; OL 170%, CL 374%, PI 330%, PG 310%, PC 190%, PE 
176% and PS 200%. 
ipin effect varied with different preparations of enzyme and 
lipid (stimulations ranged from 2.9- to 3.7-fold in the experi- 
ments described in Figs. 2 and 3), in each of the experiments 
cardiolipin stimulated autophosphorylation t  a greater extent 
than any of the other lipid activators tested (Fig. 2). Dosage 
dependence studies showed that maximum autophosphoryla- 
tion was achieved at a cardiolipin concentration of about 20 
/aM, with a sharp decrease in activity at higher concentrations, 
thus resembling the previously described cardiolipin curve for 
peptide phosphorylation [1] (Fig. 3). However, auto- 
phosphorylation was more sensitive to cardiolipin with appre- 
ciable effects (1.7-2.2-fold stimulation) evident at concentra- 
tions as low as 0.1/aM, whereas comparable effects on peptide 
phosphorylation required 10-fold higher concentrations 
(> 1/aM) (Fig. 3). 
Phosphatidylinositol and phosphatidylglycerol also stimu- 
lated PAK-1 autophosphorylation (3.3- and 3.1-fold, respec- 
tively), to nearly the same extent as cardiolipin (3.7-fold; Fig. 
2). Autophosphorylation was appreciably less affected by 
phosphatidylserine, phosphatidylcholine and phosphatidyle- 
thanolamine (2.0-, 1.9- and 1.7-fold stimulation, respectively) 
(Fig. 2). Oleic acid, the most effective activator of $6 peptide 
phosphorylation (Fig. 1), was also relatively ineffectual as a 
stimulator of autophosphorylation (l.7-fold) under assay con- 
ditions similar to those where the full effect of the fatty acid on 
the enzyme's $6 peptide kinase activity (5.8-fold) was evident 
(Fig. 2, cf. Fig. 1). 
4. Discussion 
Liver PAK-I 's unique structure, moderate abundance, re- 
stricted sensitivity to phospholipid regulators and substrate 
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Fig. 3. Cardiolipin dependency of PAK-1 autophosphorylation activ- 
ity: PAK-I autophosphorylation (©) or $6(229-239) peptide kinase (O) 
activities were assayed in the presence of 0-100 #g/ml cardiolipin. Rep- 
resentative peptide kinase data taken from experiment reported previ- 
ously [1] are shown for comparison. Autophosphorylation wasassayed 
in the presence of 50 #M ATP for 20 min at 30°C and $6 peptide kinase 
activity was assayed as in section 2. The stoichiometry of auto- 
phosphorylation was quantitated by excising gel pieces containing 
PAK-1 and determining the 32p-radioactivity b liquid scintillation 
counting. 
specificity suggests an important role in hepatic regulation [1]. 
The regulatory properties of the enzyme are characterised by 
unusually high sensitivities to cardiolipin and C18 to C20 eis- 
unsaturated fatty acids, as well as differential lipid specifities 
towards activation of its $6 peptide kinase and auto- 
phosphorylation activities. The lipid specificities, although 
overlapping, are distinct from the specificities observed for any 
of the PKCs particularly in relation to phosphatidylserine re- 
sponsiveness [4,6-8]. These properties and the unique structural 
features of its regulatory domain [26] suggest that liver PAK-1, 
together with the structurally similar protein kinases encoded 
by the recently described PKN cDNAs [3], are members of a 
new class of protein kinase within a super family of phospho- 
lipid-dependent protein kinases [1]. Of particular interest is the 
absence of the functional motifs characteristic of the PKC reg- 
ulatory domains [3,26], including the zinc finger motifs impli- 
cated in diacylglycerol binding [4,6-8] and the PKC pseudosub- 
strate motifs directly involved in the intramolecular inhibition 
of PKCs in the absence of phospholipid activators [17]. These 
structural differences can explain PAK-ls unresponsiveness to 
diacylglycerol and phorbol ester, as well as its basal $6 peptide 
kinase [1] and autophosphorylation (this paper) activities, 
which are characteristically high compared with the relatively 
very low basal activities of the PKCs [8-11]. A lack of a fully 
functional binding site for phosphatidylserine, analogous to the 
still undefined structural motif which determines the high spec- 
ificity of the PKCs for the phosphatidylserine head group [4,6], 
could explain the insensitivity of the enzyme's $6 peptide kinase 
activity to this lipid. The interaction with phosphatidylserine, 
resulting in limited activation of PAK-1 autophosphorylation 
by phosphatidylserine, only equivalent to that elicited by the 
basic phospholipids, and, insufficient to affect exogenous sub- 
strate phosphorylation, suggests non-specific interaction 
through binding to a functional site, possibly related to one of 
the sites targetted by cardiolipin or fatty acids [19]. In the case 
of the PKCs, there is evidence for more than one type of oleate 
binding site, at least, one of which is suppressed by phosphati- 
dylserine binding [19]. 
The lipid responsiveness of PAK-1, in vitro, suggests that the 
regulation of the enzyme, in vivo, involves ome form of lipo- 
philic second messenger. While cardiolipin is unlikely to be a 
physiological regulator, given its exclusive location within the 
inner mitochondrial membrane [18], it could mimmick the ac- 
tion of a more physiologically relevant phospholipid activa- 
tor(s). Candidates include phosphatidic acid which can also 
activate PAK-1, in vitro, although not as effectively as cardiol- 
ipin (Table 2, [1]), and which has been implicated as a second 
messenger in mammalian signal transduction [18-20]. Other 
potential physiological regulators include the cis-unsaturated 
fatty acids shown here to activate PAK-1 at concentrations 
(low micromolar) within the physiological range in liver. The 
high sensitivity to oleic acid distinguishes PAK-1 from the clas- 
sic PKCs which require relatively higher concentrations for 
maximal activation, are usually more responsive to arachidonic 
acid and usually exhibit synergy between fatty acids and dia- 
cylglycerol and phosphatidylserine [18,21,22]. The relatively 
high specificity for oleate compared with other C18 fatty acids, 
further suggests oleate as an intracellular regulator of PAK- 1. 
The enzyme most resembling PAK-1 with respect o oleate (as 
well as phosphatidic acid) sensitivity is the novel lipid-depend- 
ent protein kinase recently isolated from human platelets, for 
which maximun activation is achieved at ca. 10/,tM oleate [19]. 
The differential effects of the most potent activators of ex- 
ogenous ubstrate kinase activity, cardiolipin and oleic acid, on 
autophosphorylation suggest different modes of regulation of 
PAK-1. The different modes may relate to the two compart- 
ment model for the PKCs proposed by Hannun and co-workers 
[23], whereby phospholipids and diacylglycerols activate mem- 
brane bound PKCs and fatty acids selectively activate cytoplas- 
mic forms of PKCs. Differential autophosphorylation events in 
response to the different activators may help to maintain the 
enzyme in a particular compartment, aswell as influence sub- 
strate specificities and/or affinities as appears likely in the case 
of the PKCs. Accordingly, the extensive autophosphorylation 
associated with the phospholipid-type activation of PAK-1 and 
the PKCs [6,24] may facilitate the partitioning of the enzymes 
to intracellular membranes [25], while the relatively low auto- 
phosphorylation associated with oleate activation of PAK-1 
may maintain an active cytoplasmic form. Maximal activation 
by oleate in the absence of an effect on autophosphorylation 
has previously been observed with platelet PKC-cx [21], suggest- 
ing that this phenomenon could be a general feature of fatty 
acid activation of protein kinases. In this context, it will be of 
interest to determine whether the differential targetting of indi- 
vidual PKCs to different intracellular sites following activation 
[23] and the selective partitioning of the PAK- l-related recom- 
binant PKN [3] to the nuclear fraction of COS 7 cells, is influ- 
enced by autophosphorylation events. 
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